Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone lymphoma, a slow ...

Following an expedited walk along the priority review path, Bristol Myers Squibb has announced that its CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel), has been awarded US Food ...

Breyanzi (lisocabtagene maraleucel or liso-cel) was approved in February for use in LBCL patients after two prior systemic therapies, making it a third CD19-targeting CAR-T option for these ...

Bristol Myers Squibb BMY announced that the FDA has granted accelerated approval to chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel), for one more indication.

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical trials, Breyanzi has ...

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...